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Using selectable genes as proof of principle, a new high-through-
put genotype-based mutation screen in mouse embryonic stem
(ES) cells was developed [Chen et al. (2002) Nat. Genet. 24, 314–
317]. If expanded to nonselectable genes, this approach would
allow one to proceed quickly from sequence to whole-animal
phenotypes. Here data are presented showing that a screen of
a cryopreserved library of clonal, germ line competent, N-ethyl-
N-nitrosurea (ENU) mutagenized ES cells can identify a large series
of allelic mutations in Smad2 and Smad4, two nonselectable genes
of the transforming growth factor  superfamily of signaling
molecules. Whole animal phenotypic analyses of some of these
alleles provided evidence for novel developmental processes me-
diated by these components of transforming growth factor 
signaling, demonstrating the utility of non-null alleles created by
chemical mutagens. The accurately assessed mutation load of the
ES cell library indicates that it is a valuable resource for developing
mouse lines for genetic and functional studies. This methodology
can conceptually be applied for the generation of an allelic series
of subtle mutations at any locus of interest in the mouse.
A llelic series of mutations in the mouse produced by chemicalmutagens such as N-ethyl-N-nitrosourea (ENU) are valu-
able reagents to reveal a full spectrum of gene functions in vivo.
Non-null alleles are useful in particular, as they allow for
fine-tuned analysis of later functions of genes whose null allele
results in lethality and for investigation of protein domains
through isolated disruption of specific amino acid residues. The
efficiency of ENU as a mutagen has made it the mutagen of
choice in whole animal phenotype-based screens (1). Recently,
experiments have shown that mutations in specific genes of
interest can be obtained by screening DNA derived from mu-
tagenized mice and reconstituting the mouse line from cryopre-
served sperm (2). However, the large number of mice required
to identify multiple mutations in any given gene with whole-
animal mutagenesis may be prohibitive, thus more efficient
gene-based methods will be needed to produce large numbers of
subtle mutations in the mouse. We and others have shown that
mouse embryonic stem (ES) cells can be efficiently mutagenized
with chemical mutagens at several selectable loci, while retaining
their ability to populate the germ line (3, 4). If this methodology
could be extended to identify ES cells with mutations in specific
genes of interest, one could then quickly proceed from gene
sequence to developing a large allelic series of mutations in the
mouse.
Smad2 and Smad4 are vertebrate members of the Smad family
of intracellular transducers of transforming growth factor 
(TGF-) superfamily signaling (5). Current models posit Smad2
to be a receptor-regulated-Smad activated via phosphorylation
in response to ACTIVIN, TGF-, and NODAL signaling.
Smad4 is the only known mammalian common-mediator Smad
that interacts with receptor-regulated Smads after their activa-
tion. This Smad complex then translocates to the nucleus to
effect transcription of target genes through direct interaction
with a variety of other transcriptional regulators. The modula-
tion of TGF- signaling pathway by other signaling pathways,
such as the mitogen-activated protein kinase pathways, is in part
mediated by phosphorylation sites within the linker domain of
receptor-regulated Smads (6, 7). Targeted disruption of either
the murine Smad2 or Smad4 genes results in a peri-gastrulation
lethality (8). These mutants have uncovered functions of these
factors in a variety of developmental processes, including epi-
blast profileration, mesoderm formation, and extraembryonic
tissue-mediated early embryonic patterning events (8). How-
ever, the requirements for these factors in later embryonic
development and adult life remain largely unknown. Hypomor-
phic alleles that bypass the early embryonic requirement for
Smad2 and Smad4 would be useful tools to analyze the functions
of these factors in later life. Additionally, the importance of the
various protein interactions and posttranslational modification
sites in SMAD2 and SMAD4 can be analyzed in vivo with point
mutations that specifically disrupt these protein domains.
We describe here the isolation of a large allelic series of
mutations in Smad2 and Smad4 by combining ENU mutagenesis
of mouse ES cells with high throughput mutation detection
technology. Phenotypic analyses of some of these mutations in
the mouse, including a hypomorphic allele of Smad2 and a splice
mutant allele of Smad4, revealed previously undescribed func-
tions of these factors. These allelic series of mutations in Smad2
and Smad4 will serve as useful genetic tools for studying
biological processes mediated by Smad2 and Smad4. The meth-
odology can be applied to most genes to develop an allelic series
of mutations in the mouse, facilitating the functional annotation
of the mammalian genome.
Materials and Methods
ES Cell Culture and Mutagenesis. CT129 ES cells (9) were cultured
as described. The cells were grown for two passages without
feeders before ENU treatment. After the second passage onto
gelatin-coated plates, the cells were incubated with 0.2 mgml
ENU (Sigma) in culture medium for 2 h. The cells were then
washed, trypsinised, and plated at the appropriate density to
allow formation of individual colonies. Colonies were picked
into gelatin-coated 96-well plates, grown, and split in duplicate.
A total of 2,060 ES cells were picked from three separate
mutagenesis experiments. One plate was cryopreserved as a
mutagenized cell bank; the other plate was used to prepare total
RNA and genomic DNA (Qiagen, Valencia, CA) for mutation
detection.
Mutation Detection. Total RNA from ENU-mutagenized ES cell
clones was isolated for use in an RT-PCR-based amplification of
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the coding regions of mouse Smad2 and Smad4. Oligonucleo-
tides specific to Smad2 or Smad4 were used to amplify over-
lapping amplicons to cover the entire coding regions of these
genes (Table 4, which is published as supporting information
on the PNAS web site, www.pnas.org). PCR products were
denatured and annealed immediately after PCR in the thermo-
cycler. Denaturing high performance liquid chromatography
(DHPLC)-based heteroduplex analysis of the PCR products was
performed by the WAVE fragment analysis system (Trans-
genomic, Omaha, NE) using UV absorbance for detection.
Optimal DHPLC conditions for each amplicon were identified
by analysis of point mutations created by in vitro mutagenesis. ES
cell clones harboring candidate mutations were thawed and
expanded, and RNA was isolated for RT-PCR. Presence of the
mutation was confirmed by heteroduplex analysis as above. The
base change of each mutation was identified by direct sequencing
of the PCR product.
Generation of Mice. ES cell lines harboring identified point
mutations were thawed from their multiwell array and expanded.
To assess whether each line was clonal, a subcloning procedure
was performed. In brief, each ES cell line was grown and
trypsinized, and single ES cells were picked by mouth pipette
using a microscope and seeded onto feeders. After 7 days, 40
single cell colonies on these plates were picked into a multiwell
plate and subsequently split for cryopreservation and RNA
isolation. RNA was used for RT-PCR amplification and WAVE
analysis as described. If all ES cell subclones of a given line were
identified as carrying the point mutation, then the nonsubcloned
parental line was used for injection; otherwise pools of three
single-cell subclones carrying the point mutation were used for
injection into blastocysts.
Blastocyst injections for production of chimeric mice were
performed by standard procedures. Chimeras were mated to
wild-type C57BL6 or Black Swiss mice for testing germ-line
transmission. Germ-line transmission was assessed by coat color
and by genotyping with genomic DNA from tail biopsy. Geno-
typing was performed by heteroduplex analysis of PCR products
amplifying the genomic region spanning the point mutation.
Mouse stocks were maintained in the heterozygous state by
crossing heterozygous mice to wild-type mice of the desired
background for multiple generations.
Mouse Breeding. To obtain mice carrying an ENU-induced point
mutation within Smad2 or Smad4 over a targeted allele, mice
heterozygous for a point mutation were crossed to heterozygous
mice for targeted alleles of Smad2 (10) or Smad4 (11). Pups or
embryos were genotyped by using tail- or yolk sac-derived DNA,









change Region of protein†
Smad2 LM1-2G2 T523A CTG to CAG 4 L155Q MH1 turn 5
LM2-2A6 A1411G AAA to AGA 11 K451R MH2 domain, H5
LM2-2E8 G1205T CTG to CTT 10 Silent L382
LM2-3B1 T781C ATG to ACG 6 M241T Linker, CaM kinase II phosphorylation
motif (30)
m1Mag LM2-3F6 C886T TCA to TTA 8 S276L MH2, B1 sheet
LM2-4A4 A719G ACA to ACG 6 Silent T220
LM2-4H1 C183G CAA to GAA 2 Q41E MH1 helix 2, calmodulin binding domain (31)
LM2-7D9 T792G TCT to GCT 7 S245A Linker, putative proline-directed kinase site (7)
LM2-8C9 A1059G AGG to GGG 8 R334G MH2, B5 sheet
LM3-1D6 T818C ACT to ACC 7 Silent T253
LM3-2H10 T1129A ATC to AAC 9 I355N MH2, between B6 and B7 sheets
LM3-5A6 SA 7 T3G NA Int 2 RN insertion
after P78
MH1, adjacent to SMAD2 unique region
LM3-5E7 C718G ACA to AGA 6 T220K Linker, putative ERK phosphorylation site (7)
Smad4
m3Mag LM1-1H11 G1467A GGC to AGC 9 G383S MH2, B5 sheet
LM1-1H2 T1228C CAT to CAC 7 Silent H316
LM1-2H8 C812T GAC to GAT 4 Silent D164
LM2-5B6 T1945A ATG to AAG 11 M542K MH2, H5
LM2-9F5 C1529T GAC to GAT 9 Silent D403
LM3-10D7 C340T ACA to ATA 1 T7I Just N to MH1
LM3-10E2 A1588G GAC to GGC 9 D423G MH2, between H2 and B8




Deletion of QA insert and the rest of MH2
m1Mag LM3-1A6 T362A GAT to GAA 1 D14E Just N to MH1
LM3-1G1 C1607T TAC to TAT 9 Silent Y429
LM3-2E3 C1920T CTC to TTC 11 L534F MH2, H5
LM3-3D1 C1222T TAC to TAT 6 Silent Y300
LM3-3F5 C346A ACA to AAA 1 T9K Just N to MH1
m2Mag LM3-4C12 A858G ACC to GCC 4 T180A Linker, high homology with Medea (32)
LM3-7C5 C803T TAC to TAT 4 Silent Y161
LM3-7D6 C1215T CAT to TAT 6 H299Y Linker, p300 binding, transactivation
domain (33)
SA, splice acceptor; SD, splice donor; Int, intron; MH, Mad homology; NA, not applicable.
*Data are from refs. 28 and 29.
†Data are from refs. 25 and 29 unless otherwise noted.






using PCR-based methods to detect the targeted alleles as
described, and heteroduplex formation to detect the presence of
the point mutations (Table 5, which is published as supporting
information on the PNAS web site). Intercrosses of mice het-
erozygous for a point mutation were performed to obtain mice
homozygous for that mutation. Genotyping was accomplished by
heteroduplex analysis. Homozygous wild-type and homozygous
mutant PCR samples were distinguished by mixing an equimolar
amount of wild-type control PCR product, annealed and sub-
jected to heteroduplex detection.
Histology and Immunochemistry. Embryos were fixed overnight in
4% paraformaldehyde, then washed in PBS. Platelet-endothelial
cell adhesion molecule (PECAM) was detected in whole em-
bryos with an anti-PECAM antibody (PharMingen) as described
(12). Sectioning was performed by paraffin embedding and
staining with nuclear fast red or hematoxylin and eosin.
Western Blotting. The ES cells were lysed on ice for 30 min in
buffer containing 50 mM Tris (pH 7.4), 0.5% Nonidet P-40,
0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, and
protease inhibitors (Roche). The lysate was cleared of debris by
centrifugation. The total protein concentration was measured by
using the Coomassie Plus Protein Assay Reagent (Pierce). Equal
amounts of protein were separated on a SDS10% PAGE
gel and transferred to poly(vinylidene difluoride) membranes
(Millipore). The SMAD4 protein was detected by using the B-8
monoclonal antibody (Santa Cruz Biotechnology). A polyclonal
anti-ACTIN antibody (I-19, Santa Cruz Biotechnology) was used
as a control for equal loading.
Results
Identification of ENU-Induced Smad2 and Smad4 Mutations. To
screen for ES cells with mutations in specific genes of interest,
a cryopreserved library of mutagenized ES colonies was devel-
oped by using a slightly modified method of ENU treatment
from what we described (3). A total of 2,060 mutagenized ES cell
clones were cryopreserved from three separate experiments in a
96-well format to facilitate subsequent processing procedures.
Total RNA and genomic DNA were isolated from individual
mutagenized lines. Because both Smad2 and Smad4 are ex-
pressed in ES cells, RT-PCR was performed to amplify over-
lapping segments covering the entire coding regions of both
genes. When a denaturing high performance liquid chromatog-
raphy-based heteroduplex detection scheme was used (13), a
total of 29 ES cell clones were identified with mutations in
Smad2 or Smad4 (Table 1). All mutations were single nucleotide
substitutions, which is consistent with the known mutagenic
properties of ENU (14). Eighteen mutations (62%) resulted in
missense alterations of the protein. Two mutations affected
splicing through alterations in intronic sequences at the splice
junctions (15). The remaining mutations (31%) were silent. The
mutation frequencies of Smad2 and Smad4 were remarkably
similar with an overall mutation rate of 1 in 464 kb and an
average nonsilent mutation rate of 1 in 673 kb (Table 2).
Thirteen karyotypically normal cell lines carrying nonsilent
mutations were expanded for injection into blastocysts to create
chimeric mice for germ-line transmission of the ENU-generated
mutations. Consistent with our earlier work (3), mutagenized ES
cells readily made germ line competent chimeras. Five mutations
have been passed through the germ line. Complementation tests
were performed by crossing each mutation against a correspond-
Fig. 1. Severe embryonic defects associated with Smad2m1Mag mutation.
(A and B) Gross morphology of wild-type (A) and Smad2m1MagSmad2Robm1 (B)
concepti at E11.5. Smad2m1MagSmad2Robm1 concepti consist of an empty yolk
sac devoid of an embryo proper. (C) Wild-type embryo at E9.5. (D–F) Three
classes of Smad2m1MagSmad2m1Mag embryos at E9.5. (D) The empty yolk sac
closely resembles the phenotype observed in Smad2m1MagSmad2Robm1 (B). (E)
A mass of tissue at the distal tip (arrow) is observed in another class of
Smad2m1MagSmad2m1Mag embryo. This mass of tissue is contractile, indicating
the presence of some cardiac muscle differentiation. (F) The most advanced
class of Smad2m1MagSmad2m1Mag embryo exhibits many embryonic structures.
Note the expanded pericardial cavity (bracket) and truncated anterior neurec-
toderm (arrowhead).













Smad2 6.06 13 1 in 158 1 in 206 1 in 466 1 in 606
Smad4 7.40 16 1 in 129 1 in 206 1 in 463 1 in 740
Overall 13.46 29 1 in 143 1 in 206 1 in 464 1 in 673
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ing targeted mutation in addition to crossing each mutation to
homozygosity. A range of phenotypes was observed in mice
derived from these crosses.
Smad2m1Mag Is a Hypomorphic Allele. One ENU-induced allele,
Smad2m1Mag, changed a serine to leucine in amino acid 276 within
the edge of the Mad homology 2 domain. This serine residue is
conserved amongst all vertebrate and most invertebrate recep-
tor-regulated Smads, suggesting an important structural function
of this precise region of the protein. However, no protein
interactions have been localized to this region of SMAD2, nor
has there been any report of serine-276 to be phosphorylated.
Early embryonic defects were observed when the Smad2m1Mag
allele was placed against a targeted allele of Smad2, Smad2Robm1
(10). Although Smad2Smad2m1Mag littermates were normal at
11.5 days of gestation (E11.5, Fig. 1A), a highly developed yolk
sac devoid of any embryonic portion was observed in
Smad2m1MagSmad2Robm1 heterozygotes (Table 3, Fig. 1B). Yolk
sac blood islands were apparent, consistent with extraembryonic
mesoderm formation. These phenotypes closely resemble those
observed in homozygous Smad2Robm1 embryos and indicate a
substantial loss of function associated with the Smad2m1Mag
allele.
At E9.5 (Fig. 1 C–F), some homozygous Smad2m1Mag embryos
consisted of an empty yolk sac, resembling Smad2m1Mag
Smad2Robm1 and Smad2Robm1Smad2Robm1 embryos (54%, n 
34, Fig. 1D), though occasionally a malformed embryonic struc-
ture was present at the distal portion of the yolk sac (Fig. 1E).
However, many Smad2m1Mag homozygous embryos (46%) exhib-
ited considerably more advanced development. These embryos
displayed obvious epiblast-derived structures, including a heart,
tail bud, allantois, and somites (Fig. 1F). The allantois of these
embryos failed to fuse to the chorion, resulting in allantoic tissue
protruding from the posterior of the embryo (not shown). Severe
anterior patterning defects were also observed in these
Smad2m1Mag homozygous embryos. Anterior structures con-
sisted of a truncated mass often with an unfolded neural plate,
and the optic placode was not apparent. Although anterior
midline tissues were morphologically apparent in wild-type
embryos at E8.5 (Fig. 2 A and C), the absence of an anterior
notochord and a small or absent foregut were observed in
Smad2m1Mag homozygotes (Fig. 2 B and D). The advanced
embryonic development of Smad2m1MagSmad2m1Mag embryos
compared with that of the targeted alleles of Smad2, including
the ability to form many embryonic tissues, strongly suggested
that Smad2m1Mag is a hypomorph.
Vascular Defects in Smad2m1Mag Mutant Embryos. Smad2m1Mag ho-
mozygous embryos with fused heart tubes displayed an expanded
pericardial cavity (Fig. 1F) and erratic cardiac contractility,
suggesting that cardiovascular defects may cause the embryonic
lethality observed in these embryos after E9.5. Because vascular
defects have been observed in several mutants of other TGF-
signaling components (16), the early embryonic vasculature was
visualized with an anti-PECAM antibody. Although endothelial
cells were present in both wild-type and mutant embryos (Fig. 2
E and F), the dorsal aorta in these Smad2m1Mag homozygotes was
either highly constricted or lacked an aortic lumen present at this
time in wild-type embryos (Fig. 2 G and H) and was generally
more severe in the anterior of the embryo. The defects observed
in Smad2m1Mag homozygous embryos confirmed the requirement
for Smad2 in the proper formation of the anterior neurectoderm
and foregut and demonstrate a function for Smad2 in cho-
rioallantoic fusion and vascular development.
Fig. 2. Defects in the formation of the dorsal aorta, foregut, and notochord in Smad2m1MagSmad2m1Mag embryos. (A–D) Hematoxylin and eosin staining of transverse
histological sections of wild-type (A and C) and Smad2m1MagSmad2m1Mag (B and D) embryos at E9.5 about the level of the heart at 10 (A and B) and 20 (C and D)
objective magnification. Smad2m1MagSmad2m1Mag embryos display a small foregut (FG) compared with wild type and lack a morphologically obvious notochord (No).
(E and F) Ventral view of the dorsal aortae (DA) at the region of the opening of the foregut of intact wild-type (E) and Smad2m1MagSmad2m1Mag (F) embryos at E8.5
visualizedwithananti-PECAMantibody.Significantendothelialdifferentiation isobserved inmutantembryosbuttheaortafails tocondensefully. (GandH)Transverse
sectionsofPECAM-stainedembryosat the levelof theforegutentranceofwild-type (G) andSmad2m1MagSmad2m1Mag (H) embryosatE8.5.Thecellsof thedorsalaortae
display strong PECAM expression about the aortic lumen in wild-type embryos. Although PECAM-positive endothelial cells are present in mutant embryos (H,
arrowhead), cells fail to form an aortic lumen in this region of the embryo.
Table 3. Complementation tests with targeted alleles (KO)
ENU allele*  ENU KO ENUKO Total
Smad2m1Mag 14 6 8 0 (4)† 32
Smad4m1Mag 14 15 6 6 41
Smad4m2Mag 22 20 19 21 82
Smad4m3Mag 14 18 19 18 69
Smad4m4Mag 14 16 17 0 47
*Smad2 analysis was performed at E9.5 to E11.5. Smad4 analysis was per-
formed at postnatal stages.
†All Smad2m1MagSmad2Robm1 concepti consisted of an empty yolk sac.






Viability of Several ENU-Induced Smad4 Alleles. Three of the four
ENU-induced Smad4 alleles (Smad4m1Mag, Smad4m2Mag, and
Smad4m3Mag) resulted in missense substitutions of conserved
amino acid residues (Table 1). Surprisingly, animals carrying
each of these mutations survived to adulthood either in combi-
nation with the targeted Smad4tm1Cxd allele (17) or in the
homozygous state (Table 3), indicating that these missense
substitutions do not significantly perturb the functions of the
SMAD4 protein during embryogenesis. To date, these animals
have been aged for at least 5 months, and no overt phenotypes
have been observed either in the compound heterozygotes or
homozygotes.
Smad4m4Mag Is a Splice Mutant Allele. The fourth Smad4 allele,
Smad4m4Mag, altered a conserved nucleotide in the splice donor
of the intron 10, causing the deletion of exon 10. This aberrant
transcript is predicted to produce a truncated protein with an
additional 19 out-of-frame amino acids after amino acid 436 in
the highly conserved Mad homology 2 domain. Consistent with
the drastic alteration in the gene product, mice that are com-
pound heterozygous for the Smad4m4Mag allele and the targeted
allele Smad4tm1Cxd did not survive embryogenesis (Table 3).
Compared with the wild-type E7.5 embryo (Fig. 3A), these
animals were severely growth-retarded, failed to initiate gastru-
lation and consequently did not form mesoderm (Fig. 3C).
Animals homozygous for Smad4m4Mag displayed similar pheno-
types (Fig. 3D) and closely resembled those of the Smad4tm1Cxd
homozygotes (Fig. 3B), indicating a severe loss of function
associated with the Smad4m4Mag allele. However, examination of
the steady-state SMAD4 protein levels in Smad4m4Mag heterozy-
gous ES cells revealed that Smad4m4Mag is not a conventional null
allele. Wild-type SMAD4 protein levels in the Smad4m4Mag
heterozygous ES cell lines were dramatically lower than the
expected level of 50% (Fig. 3E). Additionally, no truncated
mutant SMAD4 protein, predicted to be 51 kDa, was detected.
Similar reduction of the wild-type SMAD4 protein level as well
as the absence of the truncated protein was also seen in primary
embryonic fibroblasts of Smad4m4Mag heterozygotes (data not
shown). The reduction of wild-type protein indicates that not
only is the truncated mutant protein unstable, it possibly confers
instability to the wild-type protein as well in heterozygous cells,
suggesting a dominant negative property of the Smad4m4Mag
allele.
Discussion
Our results demonstrate that combining chemical mutagenesis in
mouse embryonic stem cells with high throughput mutation
detection allows for the rapid identification of subtle mutations
in nonselectible genes of interest. A variety of alleles can be
quickly obtained in a modest sized genotype-based screen. Thus
far we have obtained three viable alleles (Smad4m1Mag,
Smad4m2Mag, Smad4m3Mag), a hypomorphic allele (Smad2m1Mag),
and an allele (Smad4m4Mag) that resembles the null allele in the
homozygous state but acts molecularly as a dominant negative in
the heterozygous state.
Assessment of Mutation Load in Genotype-Based Screens. Although
predictions of mutation load have been attempted from whole
animal phenotype-based screens (18), only with the recent
introduction of genotype-based screens in the mouse has a
per-base assessment of mutation load been possible (2, 18).
However, highly differing numbers have been reported because
of differences in sample size, the mutagen dose and the sensi-
tivity of the mutation identification methods. The large sample
size of our screen and consistent mutation frequencies between
two independent loci indicate an accurate assessment of muta-
tion load in our cryopreserved bank. With a mutation frequency
of 1 in 464 kb, the average distribution of nonsilent coding
sequence variations in this ES cell library is 1 per 13 centi-
morgans (cM), assuming a 1,600-cM, 2.7 Gb haploid mouse
genome of which 3% is coding. Thus, the ES cell library is a
useful reagent for developing mouse lines carrying mutations at
specific loci. It is worth noting that a similar mutation frequency
of 1 sequence variation per 482 kb was observed in a genotype-
based screen in zebrafish exposed to a dose of ENU typically
used in phenotype-driven screens (19). If desired, mutagenesis
procedures can be readily altered in cell culture to lower
mutation load, taking advantage of the ability to monitor the
mutation load of a cryopreserved library in culture with select-
able loci. Phenotypic analysis of mutations obtained in any
chemical mutagenesis would be best analyzed by using com-
pound heterozygotes, possibly by using alleles with similar
phenotypic severity, which requires multiple mutant alleles of a
gene. The high throughput nature of the ES-cell-based genotypic
screen allows for the rapid development of such allelic series of
mutations.
Smad2m1Mag Is a Tool to Analyze Smad2 Function in Embryonic Devel-
opment. The Smad2m1Mag allele demonstrates the utility of subtle
mutations for uncovering previously uncharacterized gene func-
tion. Owing to the advanced development of some of these
Fig. 3. Defects associated with the Smad4m4Mag allele. Hematoxylin and
eosin-stained sagittal sections of E7.5 embryos are shown. (A) Wild-type
gastrulating embryo showing newly formed mesoderm (arrow) and other well
patterned structures. (B) Homozygous Smad4tm1Cxd embryo. (C) Smad4m4Mag
Smad4tm1Cxd embryo. (D) Homozygous Smad4m4Mag embryo. (B–D) Compared
with the wild-type E7.5 embryo (A), these mutant embryos are much smaller,
with no sign of the initiation of gastrulation or the formation of mesoderm.
Also note the disproportionally large cavity between the visceral and parietal
endoderm (asterisks). (E) Steady-state level of SMAD4 protein in un-
mutagenized wild-type ES cells (lane 1) and three mutagenized sibling sub-
clones (lane 2, wild-type for Smad4; lanes 3 and 4, heterozygous for
Smad4m4Mag). The same blot was stripped and reprobed with an anti-ACTIN
antibody to show equal loading of total cellular proteins.
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mutants, the ENU induced Smad2m1Mag allele suggests require-
ments for Smad2 not revealed in any Smad2 targeted mutation,
including functions in chorioallantoic fusion and cardiovascular
development. Additionally, this allele confirms functions for
Smad2 in anterior development and endoderm formation (20,
21). The less severe class of Smad2m1Mag homozygous embryos is
likely due to a partial or full rescue of the requirement of Smad2
in extraembryonic tissues to pattern the epiblast (10), suggesting
that the mouse embryo must be highly sensitive to threshold
levels of TGF--related signaling in extraembryonic tissues to
mediate early embryo patterning. The distinct phenotypic classes
of defects observed in Smad2m1Mag homozygotes resemble those
observed in a hypomorphic allele of nodal, confirming the
requirement for Smad2 in mediating NODAL signaling in a
variety of embryonic stages (20).
Mutations in several other components of TGF- signaling
result in defects in vascular development, including Alk1, Smad5,
and TGF-1, which have similar phenotypes, including an en-
larged dorsal aorta (16). The failure of normal dorsal aorta
formation in Smad2m1Mag homozygotes appears phenotypically
different from these mutations, suggesting that the Smad2m1Mag
allele has uncovered potentially novel aspects of TGF--related
signaling in vascular development. One intriguing possibility is
that the notochord or foregut defects observed in Smad2m1Mag
homozygotes underlie the vascular defects in these embryos. The
failure of endoderm formation in Smad2m1Mag homozygotes is
consistent with previous data showing that Smad2-deficient cells
do not efficiently contribute to the definitive endoderm lineage
(21). The Smad2m1Mag allele will thus provide a useful tool to
analyze Smad2-mediated endoderm development, as well as the
functional consequences of loss of endoderm-derived tissues in
the early embryo.
SMAD4 Truncation Mutations and Dominant Negative Activities. Sev-
eral studies have shown that C-terminal truncations of the
SMAD4 protein display dominant negative properties (22, 23) or
are highly unstable and rapidly degraded via the ubiquitin-
proteasome pathway (24). Although the Smad4m4Mag splice
mutation deletes the C-terminal helix bundle thought to be
important for homo-oligomerization (25), its intact Mad homol-
ogy 1 domain, the linker region, and the remaining Mad
homology 2 domain may be sufficient for oligomerization with
the wild-type SMAD4 protein. Similar C-terminal truncations of
SMAD4 protein have been shown to retain their ability to
interact with the full-length wild-type protein (26). As cellular
SMAD4 is found mostly in a homo-oligomer state (27), the
decreased wild-type SMAD4 protein in the Smad4m4Mag het-
erozygous cells could be due to the association of mutant protein
with the wild-type protein, which is then targeted for degrada-
tion. It is remarkable that the heterozygous ES cells and animals
are phenotypically normal despite the low levels of SMAD4
protein, suggesting a low threshold level of SMAD4 protein
required for normal development and function in the cell and
tissue types examined. The nonallelic, noncomplementation of
some of the receptor-regulated Smads (28) underscores the
dosage sensitive aspect of the TGF--related signaling. The
apparent dominant negative property of the Smad4m4Mag allele
and hypomorphic nature of the Smad2m1Mag allele will provide
unique sensitized backgrounds both in vitro and in vivo for
studying the importance of these factors in various biological
processes.
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